Fig. 3
From: CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth
CYD0281 inhibits angiogenic differentiation of HUVECs in vitro. Representative microscopic images and quantification of cell migration (A), and tube formation in Matrigel (B). C Representative images of endothelial cells sprout and quantification from rat aortic ring assay at 8 days of treatment. Significant effect compared to the DMSO group: **P < 0.01 and ***P < 0.001. Scale bars: 100 μm (A and B) and 500 μm (C)